Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The ...

Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. Marvai, a San Diego company, said Tuesday that the acquisition would expand the ...

1 Day MRVI -8.55% DJIA -0.31% S&P Mid Cap 400 -0.41% Health Care/Life Sciences 0.39% ...

EST Maravai Lifesciences (MRVI) jumps 6% to $5.85 after MAI IP acquisition announcementInvest with Confidence: Follow TipRanks' Top Wall ...

Maravai LifeSciences (NASDAQ:MRVI) said on Wednesday that based on preliminary year-end results, the company expects to report total 2024 revenue near the mid-point of the previously announced ...

Throughout the last three months, 4 analysts have evaluated Maravai LifeSciences (NASDAQ:MRVI), offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral ...

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period. The most recent guidance for Maravai ...

Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and ...

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...